EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology

Matthias Höllerhage, Jos Becktepe, Joseph Classen, Günther Deuschl, Georg Ebersbach, Franziska Hopfner, Paul Lingor, Matthias Löhle, Sylvia Maaß, Monika Pötter-Nerger, Per Odin, Dirk Woitalla und 3 weitere

Journal of Neurology · 2024-11 · 271 (11) · 7071-7101

DOI: 10.1007/s00415-024-12632-6 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Neurology, online erschienen am 29.08.2024. Verfasst von Matthias Höllerhage und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Antiparkinson Agents, Neurology, Parkinson Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Gesellschaft für Neurologie, Klinikum der Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objective There are multiple pharmacological treatment options for motor symptoms of Parkinson’s disease (PD). These comprise multiple drug classes which are approved for the condition, including levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors, NMDA-receptor antagonists, anticholinergics, and others. Some of the drugs are approved for monotherapy and combination therapy while others are only approved as adjunctive therapy to levodopa. Furthermore, treatment for special treatment situations, e.g., rescue medication for off-phases, for tremor, treatment during pregnancy and breast feeding is discussed and recommendations are given with further details.

Methods

The recommendations were based on systematic literature reviews, drafted by expert teams, consented in online polls followed by online consensus meetings of the whole German Parkinson’s Guideline Group, and publicly released in November 2023.

Results

In the new S2k (i.e., consensus-based) guidelines, the pharmacotherapy of the motor symptoms of PD is discussed in five chapters. These comprise “Parkinson medication”, “Initial monotherapy”, “Early combination therapy”, “Fluctuations and dyskinesia”, and “Parkinsonian tremor”. Furthermore, there is a chapter for special treatment situations, including perioperative management, freezing of gait, and pregnancy and breastfeeding.

Conclusion

The recommendations for the pharmacotherapy of motor symptoms of PD have been updated. Newly available drugs have been added, while other drugs (e.g., ergoline dopamine agonists, anticholinergics, budipine) have been removed from the recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiparkinson AgentsNeurologyParkinson DiseaseHumansGermanySocieties, MedicalSystematic Reviews as TopicPractice Guidelines as Topic

Stichwörter der Autor:innen

GuidelinesParkinson's diseasePharmacotherapy

Substanzen

Antiparkinson Agents

Autor:innen und Institutionen

  • Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Department of Neurology, Christian-Albrechts-University, Kiel, Germany.
  • Department of Neurology, Leipzig University Medical Center, Leipzig, Germany.
  • Movement Disorders Hospital, Beelitz-Heilstätten, Germany.
  • Department of Neurology with Friedrich Baur Institute, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Marchioninistr. 15, 81377, Munich, Germany.
  • School of Medicine and Health, Department of Neurology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.

Förderung

  • Deutsche Gesellschaft für Neurologie
  • Klinikum der Universität München

Zitieren

APA

Höllerhage, M., Becktepe, J., Classen, J., Deuschl, G., Ebersbach, G., Hopfner, F., Lingor, P., Löhle, M., Maaß, S., Pötter-Nerger, M., Odin, P., Woitalla, D., German Parkinson’s Guidelines Group, Trenkwalder, C., & Höglinger, G. U. (2024). Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology. Journal of Neurology, 271(11), 7071-7101. https://doi.org/10.1007/s00415-024-12632-6

Vancouver

Höllerhage M, Becktepe J, Classen J, Deuschl G, Ebersbach G, Hopfner F, et al. Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology. Journal of Neurology. 2024;271(11):7071-7101. doi:10.1007/s00415-024-12632-6

BibTeX
@article{Hllerhage2024,
  author = {Höllerhage, Matthias and Becktepe, Jos and Classen, Joseph and Deuschl, Günther and Ebersbach, Georg and Hopfner, Franziska and Lingor, Paul and Löhle, Matthias and Maaß, Sylvia and Pötter-Nerger, Monika and Odin, Per and Woitalla, Dirk and German Parkinson’s Guidelines Group, German Parkinson’s Guidelines Group and Trenkwalder, Claudia and Höglinger, Günter U},
  title = {Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology},
  journal = {Journal of Neurology},
  year = {2024},
  volume = {271},
  number = {11},
  pages = {7071--7101},
  doi = {10.1007/s00415-024-12632-6}
}
Kostenlos starten →